DOTmed April 15, 2025
RadNet Inc. has entered into a definitive agreement to acquire iCAD Inc. in an all-stock transaction valued at approximately $103 million.
The deal is aimed at expanding RadNet’s footprint in AI-driven breast cancer detection through the integration of iCAD’s technology and international customer base.
Shareholders of the Nashua, New Hampshire-based iCAD will receive 0.0677 shares of RadNet common stock for each share of iCAD common stock. Based on RadNet’s closing price on April 14, the offer represents a roughly 98% premium over iCAD’s most recent stock price.
Los Angeles-based RadNet plans to integrate iCAD into its DeepHealth subsidiary, which focuses on artificial intelligence applications for diagnostic imaging. iCAD’s portfolio, including the ProFound Breast Health Suite, will be added to DeepHealth’s...
Today's Sponsors
Today's Sponsor